Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsors and Collaborators: |
University of Florida FDA Office of Orphan Products Development |
---|---|
Information provided by: | University of Florida |
ClinicalTrials.gov Identifier: | NCT00432744 |
Our central hypothesis is that oral CoQ10 is a safe and effective treatment for children with inborn errors of mitochondrial energy metabolism due to defects in specific respiratory chain (RC) complexes or mitochondrial DNA (mtDNA) mutations, and that this beneficial action is reflected in improved motor and neurobehavioral function and in quality of life.
Condition | Intervention | Phase |
---|---|---|
Mitochondrial Diseases |
Drug: CoenzymeQ10 Drug: Coenzyme Q10 Drug: Placebo |
Phase III |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator), Placebo Control, Crossover Assignment, Safety/Efficacy Study |
Estimated Enrollment: | 50 |
Study Start Date: | January 2007 |
Estimated Study Completion Date: | May 2009 |
Estimated Primary Completion Date: | May 2009 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
1: Active Comparator
Draw CoQ10 troughs every three months
|
Drug: CoenzymeQ10
Draw CoQ10 troughs every three months
Drug: Coenzyme Q10
10 mg/k daily up to 400 mg
|
2: Placebo Comparator
Placebo
|
Drug: Placebo
Placebo daily
|
This postulate will be tested by accomplishing the following specific aims:
Specific Aim 1. Conduct a multicenter, prospective, randomized, double-blind, placebo controlled crossover trial of oral CoQ10 in children with biochemically proven deficiencies of complex I, III or IV of the RC or with mutations of a gene coding for an RC component (mtDNA and nDNA). This aim tests the hypothesis that supplementation with CoQ10 (10 mg/kg/d) is safe and more effective in improving outcome than placebo. General Clinical Research Centers (GCRCs) or similar facilities will be the venues for this phase 3 clinical trial.
Specific Aim 2. Determine the effectiveness of CoQ10 in improving the morbidity of affected patients. This aim addresses the postulate that high dose CoQ10 improves quality of life and motor function as determined by a validated questionnaire for this patient population, and by objective, standardized measures of motor function.
Specific Aim 3. Determine the safety of CoQ10 in the target population. This aim tests the postulate that the formulation and dose of CoQ10 employed is well tolerated and the administration of this product is not associated with significantly more numerous or more severe adverse events than is administration of placebo.
Ages Eligible for Study: | 12 Months to 17 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contact: Peter W Stacpoole, PhD, MD | 352/392-2321 | peter.stacpoole@medicine.ufl.edu |
Contact: Lesa R Gilbert, RN | 888/961-9068 | lesa.gilbert@medicine.ufl.edu |
United States, Ohio | |
Case Western Reserve University | Recruiting |
Cleveland, Ohio, United States, 44106 | |
Contact: Shawn McCandless, MD 216-844-1612 sxm32@case.edu | |
Contact: Janice Bartos, RN (216) 844-7124 janice.bartos@uhhs.com | |
Principal Investigator: Douglas S. Kerr, MD, PhD | |
Cincinnati Children's Hospital Medical Center | Recruiting |
Cincinnati, Ohio, United States, 45267 | |
Contact: Ton J deGrauw, MD, PhD 513-636-8680 t.degrauw@cchmc.org | |
Contact: Gail Chuck, RN (513) 636-8016 gail.chuck@cchmc.org | |
Principal Investigator: Ton J deGrauw, MD, PhD | |
Canada, Ontario | |
Hospital for Sick Children | Recruiting |
Toronto, Ontario, Canada, M5G 1X8 | |
Contact: Annette S. Feigenbaum, MD (416) 813-5340 annette.feigenbaum@sickkids.ca | |
Contact: Mohammed Hussain (416) 813-7654 ext 2646 mohammed.hussain@sickkids.ca | |
Principal Investigator: Annette S. Feigenbaum, MD |
Principal Investigator: | Douglas S. Kerr, MD, PhD | Case Western Reserve University |
Principal Investigator: | Ton J deGrauw, MD, PhD | Children's Hospital Medical Center, Cincinnati |
Principal Investigator: | Annette S. Feigenbaum, MD | SickKids, Toronto, Canada/University of Toronto |
Responsible Party: | UFlorida ( Peter W. Stacpoole, PhD, MD ) |
Study ID Numbers: | 1 R01 FD003032-01A1 |
Study First Received: | February 6, 2007 |
Last Updated: | June 4, 2008 |
ClinicalTrials.gov Identifier: | NCT00432744 |
Health Authority: | United States: Food and Drug Administration |
mitochondrial diseases respiratory chain complex I deficiencies respiratory chain complex II deficiencies |
respiratory chain complex III deficiencies respiratory chain complex IV deficiencies mutations of a gene coding for a respiratory chain component |
Metabolic Diseases Ubiquinone Metabolic disorder Mitochondrial Diseases Coenzyme Q10 |
Vitamins Growth Substances Physiological Effects of Drugs Micronutrients Pharmacologic Actions |